Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth M Garry

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Drug Safety|March 13, 2015
Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a reviewElisabetta Patorno, Elizabeth M Garry, Amanda R Patrick, et al.
Clinical and Translational Science|June 6, 2022
Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort studyDina Oksen, Patricia Prince, Emmanuelle Boutmy, et al.
Diabetologia|September 13, 2014
Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitationsElisabetta Patorno, Amanda R Patrick, Elizabeth M Garry, et al.
Pharmacoepidemiology and Drug Safety|August 5, 2025
Evaluating the Impact of Data Standardization on Real-World DataElizabeth M Garry, Aidan Baglivo, Priya Govil, et al.
Pharmacoepidemiology and Drug Safety|January 13, 2025
Characterization of SARS-CoV-2 Diagnostic Tests and Liver Function Tests Among Patients With COVID-19 Diagnosed in Outpatient Settings Using Administrative Healthcare Data and Data From Commercial LaboratoriesAyad K Ali, Aidan Baglivo, Priya Govil, et al.
Plos One|September 26, 2022
Describing characteristics and treatment patterns of patients hospitalized with COVID-19 by race and ethnicity in a national RWD during the early months of the pandemicSarah E Vititoe, Imaani J Easthausen, Tamar Lasky, et al.
Journal of Managed Care & Specialty Pharmacy|November 29, 2019
Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with DiabetesElizabeth M Garry, Sebastian Schneeweiss, Sara Eapen, et al.
Circulation|December 17, 2020
Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE InitiativeJessica M Franklin, Elisabetta Patorno, Rishi J Desai, et al.
Pharmacoepidemiology and Drug Safety|April 4, 2022
Categorization of COVID-19 severity to determine mortality riskElizabeth M Garry, Andrew R Weckstein, Kenneth Quinto, et al.
Epidemiology (Cambridge, Mass.)|September 25, 2025
Illustrating an Adaptive Prespecification Framework for Observational Research: Target Trial Emulations Comparing Immunomodulator Treatments for COVID-19Andrew R Weckstein, Vera Frajzyngier, Sarah E Vititoe, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Drug Safety|March 13, 2015
Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a reviewElisabetta Patorno, Elizabeth M Garry, Amanda R Patrick, et al.
Clinical and Translational Science|June 6, 2022
Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort studyDina Oksen, Patricia Prince, Emmanuelle Boutmy, et al.
Diabetologia|September 13, 2014
Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitationsElisabetta Patorno, Amanda R Patrick, Elizabeth M Garry, et al.
Pharmacoepidemiology and Drug Safety|August 5, 2025
Evaluating the Impact of Data Standardization on Real-World DataElizabeth M Garry, Aidan Baglivo, Priya Govil, et al.
Pharmacoepidemiology and Drug Safety|January 13, 2025
Characterization of SARS-CoV-2 Diagnostic Tests and Liver Function Tests Among Patients With COVID-19 Diagnosed in Outpatient Settings Using Administrative Healthcare Data and Data From Commercial LaboratoriesAyad K Ali, Aidan Baglivo, Priya Govil, et al.
Plos One|September 26, 2022
Describing characteristics and treatment patterns of patients hospitalized with COVID-19 by race and ethnicity in a national RWD during the early months of the pandemicSarah E Vititoe, Imaani J Easthausen, Tamar Lasky, et al.
Journal of Managed Care & Specialty Pharmacy|November 29, 2019
Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with DiabetesElizabeth M Garry, Sebastian Schneeweiss, Sara Eapen, et al.
Circulation|December 17, 2020
Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE InitiativeJessica M Franklin, Elisabetta Patorno, Rishi J Desai, et al.
Pharmacoepidemiology and Drug Safety|April 4, 2022
Categorization of COVID-19 severity to determine mortality riskElizabeth M Garry, Andrew R Weckstein, Kenneth Quinto, et al.
Epidemiology (Cambridge, Mass.)|September 25, 2025
Illustrating an Adaptive Prespecification Framework for Observational Research: Target Trial Emulations Comparing Immunomodulator Treatments for COVID-19Andrew R Weckstein, Vera Frajzyngier, Sarah E Vititoe, et al.
Pageof 4